WallSt Focus
                    Total 973 Posts
                
                
            TikTok Ban in the Balance: Supreme Court to Hear ByteDance’s Appeal
                The ongoing legal battle over the potential U.S. ban of TikTok took a turn this week as the Supreme Court agreed to hear a case challenging a law that could force ByteDance, TikTok’s China-based parent company, to sell the popular app by January 19 or face a nationwide ban.
            
        Wholesale Inflation Surges to 3%, Complicating Fed’s Rate Cut Outlook
                Wholesale prices surged more than anticipated in November, with the Producer Price Index (PPI) rising 3% year-over-year, according to the Bureau of Labor Statistics (BLS).
            
        SMCI Investigation Sparks Rally—Should Investors Be Concerned About Lingering Issues?
                SMCI’s shares surged after an independent investigation found no evidence of fraud and the special committee's recommendation to strengthen governance has calmed some investor fears.
            
        Stock Market Today: Stocks Wobble As Inflation Data Clouds Fed Rate Cut Bets
                On Thursday, the stock market struggled for direction as new inflation data added uncertainty to the Federal Reserve's next policy move.
            
        GM’s $1 Billion Stake Sale: Is the Carmaker Rethinking Its Battery Strategy?
                GM has recently been in the news after it announced the sale of its stake in a $2.6 billion battery cell plant in Lansing, Michigan, to JV partner LG Energy Solution for approximately $1 billion.
            
        October PCE Data Sparks Debate on Inflation Progress and Fed Policy
                The October reading of the Federal Reserve's preferred inflation gauge, the Personal Consumption Expenditures (PCE) index, is giving mixed signals.
            
        The Biotech Stock Soaring 63% on Unprecedented Cancer Trial Results – Meet Janux Therapeutics
                On December 3, 2024, the company announced groundbreaking results for its lead drug candidate, JANX007, a tumor-activated T-cell engager targeting advanced-stage prostate cancer.